Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Beigene ADS Representing Ord Shs ONC

Healthcare Biotechnology
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the... see more

Recent & Breaking News (NDAQ:ONC)

BeiGene Appoints Corsee Sanders, Ph.D. to its Board of Directors

Business Wire August 25, 2020

Bio-Thera Solutions and BeiGene Announce License, Distribution, and Supply Agreement for Avastin® (Bevacizumab) Biosimilar BAT1706 in China

Business Wire August 24, 2020

BeiGene Reports Second Quarter 2020 Financial Results

GlobeNewswire August 6, 2020

BeiGene Announces Data on Tislelizumab and Pamiparib to Be Presented at the 2020 European Society for Medical Oncology (ESMO) Virtual Congress

GlobeNewswire August 5, 2020

Priority Review Granted to BeiGene's New Drug Application of Pamiparib in Ovarian Cancer in China

GlobeNewswire July 27, 2020

Assembly Biosciences and BeiGene Announce License and Collaboration Agreement in China for Assembly's Portfolio of Three Clinical-Stage Core Inhibitors for Chronic Hepatitis B Infection

GlobeNewswire July 20, 2020

BeiGene Announces Acceptance of a New Drug Application of Pamiparib in Ovarian Cancer in China

GlobeNewswire July 17, 2020

BeiGene Announces Closing of Approximately $2.08 Billion Registered Direct Offering

GlobeNewswire July 15, 2020

BeiGene Announces Pricing of Approximately $2.08 Billion Registered Direct Offering

GlobeNewswire July 12, 2020

BeiGene to Host Investor Conference Call and Webcast to Discuss the Company's Early Development Pipeline and Research

GlobeNewswire July 2, 2020

BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Patients with Previously Treated Unresectable Hepatocellular Carcinoma in China

GlobeNewswire July 1, 2020

BeiGene Announces Appointment of Angus Grant as Chief Business Executive

GlobeNewswire July 1, 2020

BeiGene Begins Commercializing XGEVA® (Denosumab) in China

GlobeNewswire June 30, 2020

BeiGene and SpringWorks Announce Presentation of Preclinical Data Combining RAF Dimer Inhibitor Lifirafenib with MEK Inhibitor Mirdametinib and Provide Update on Ongoing Phase 1b/2 Clinical Trial

GlobeNewswire June 22, 2020

BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination with Chemotherapy in First-Line Advanced Non-Squamous Non-Small Cell Lung Cancer in China

GlobeNewswire June 19, 2020

BeiGene Announces European Medicines Agency Acceptance of its Marketing Authorization Application for BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Waldenström's Macroglobulinemia

GlobeNewswire June 18, 2020

BeiGene Presents Clinical Data on Zanubrutinib and Tislelizumab at the 25th European Hematology Association (EHA) Virtual Congress

GlobeNewswire June 12, 2020

BeiGene to Present at the Goldman Sachs 41st Annual Global Healthcare Conference

GlobeNewswire June 5, 2020

BeiGene Announces the Approval of BRUKINSA(TM) (Zanubrutinib) in China for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Relapsed/Refractory Mantle Cell Lymphoma

GlobeNewswire June 3, 2020

BeiGene Presents Phase 3 Data on Tislelizumab Combined with Chemotherapy for the Treatment of Patients with Advanced Squamous Non-Small Cell Lung Cancer at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program

GlobeNewswire May 29, 2020